drugset / Trial / NCT02017704
Chemoradiation or Brachytherapy for Rectal Cancer
Phase 2
Completed
9 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Elekta Limited · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This research is being done to compare the effectiveness of high dose endorectal brachytherapy (END-HDR) and the standard treatment option of chemoradiation with Capecitabine in the treatment of cancer of the lowest part of the bowel (rectum).
Timeline
- Start
- 2014-06-12
- Primary completion
- 2021-09-30
- Completion
- 2023-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | 825 mg/m2 | — |
| Background | Leucovorin | Small molecule | 400 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Other |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |